SEPTEMBER 2025
Is this the future of in vivo gene delivery?
AAV has long dominated the spotlight in gene therapy. But a powerful contender is stepping into the ring. Lentiviral vectors (LVVs), once confined to ex vivo applications, are reemerging as the delivery system poised to transform in vivo treatments.
From autoimmune disorders to CNS diseases, LVVs are rewriting the rules with:
Unmatched payload capacity for complex therapeutic designs
Programmable expression systems to fine-tune safety and efficacy
Scalable, GMP-ready manufacturing innovations that remove bottlenecks
With advanced targeting, safer integration, and modular design, LVVs may be the most versatile tools yet for next-generation gene therapies.
Read the article, co-authored by David Darling, Ph.D., and Glenda Joanne Dickson, Ph.D., of ViroCell Biologics.